Armata Pharmaceuticals, Inc. (ARMP) Form 8-K — Jul 20, 2026
Armata Pharmaceuticals appointed David House as Chief Financial Officer, effective July 17, 2026. Mr. House previously served as the company's Senior Vice President, Finance and principal financial officer since August 2024. Pursuant to his new employment agreement, Mr.
Key figures
- Cfo Base Salary
- 371315
- Cfo Severance Months
- 12
- Cfo Equity Target Value
- 300000
- Cfo Bonus Target Percent
- 50
Price after filing
1 day: +2.0%7 days: +1.8%30 days: +0.2%
Close on the filing date to close N calendar days later (from $5.06). Historical, not a forecast.
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.